| Anaemia | Blood and lymphatic system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Acute myocardial infarction | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Angina pectoris | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0023 affected323 at risk
|
| Angina unstable | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0022 affected323 at risk
|
| Aortic valve stenosis | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0002 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Arrhythmia | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0002 affected318 at risk
- EG0012 affected329 at risk
- EG0020 affected323 at risk
|
| Atrial fibrillation | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0006 affected318 at risk
- EG0017 affected329 at risk
- EG0022 affected323 at risk
|
| Atrioventricular block | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Atrioventricular block complete | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0002 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Atrioventricular block second degree | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Atrioventricular dissociation | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Bradycardia | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0011 affected329 at risk
- EG0022 affected323 at risk
|
| Cardiac arrest | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0004 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Cardiac disorder | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Cardiac failure | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0022 affected323 at risk
|
| Cardiac failure congestive | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0004 affected318 at risk
- EG0013 affected329 at risk
- EG0028 affected323 at risk
|
| Coronary artery disease | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0002 affected318 at risk
- EG0011 affected329 at risk
- EG0022 affected323 at risk
|
| Coronary artery occlusion | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Left ventricular dysfunction | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Left ventricular failure | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0012 affected329 at risk
- EG0020 affected323 at risk
|
| Mitral valve incompetence | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Mitral valve prolapse | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Myocardial infarction | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0002 affected318 at risk
- EG0012 affected329 at risk
- EG0021 affected323 at risk
|
| Myocardial ischaemia | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Tachycardia | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Ventricular fibrillation | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Ventricular tachycardia | Cardiac disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0012 affected329 at risk
- EG0020 affected323 at risk
|
| Arteriovenous malformation | Congenital, familial and genetic disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Deafness unilateral | Ear and labyrinth disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Hypoacusis | Ear and labyrinth disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Vertigo | Ear and labyrinth disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0013 affected329 at risk
- EG0020 affected323 at risk
|
| Blindness transient | Eye disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0012 affected329 at risk
- EG0022 affected323 at risk
|
| Choroidal neovascularisation | Eye disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0011 affected329 at risk
- EG0022 affected323 at risk
|
| Dry age-related macular degeneration | Eye disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0013 affected329 at risk
- EG0023 affected323 at risk
|
| Glaucoma | Eye disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Neovascular age-related macular degeneration | Eye disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0002 affected318 at risk
- EG0011 affected329 at risk
- EG0024 affected323 at risk
|
| Open angle glaucoma | Eye disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Optic ischaemic neuropathy | Eye disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Ulcerative keratitis | Eye disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Uveitic glaucoma | Eye disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Visual acuity reduced | Eye disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG00010 affected318 at risk
- EG00113 affected329 at risk
- EG00218 affected323 at risk
|
| Visual impairment | Eye disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Vitreous floaters | Eye disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Vitreous haemorrhage | Eye disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Abdominal hernia | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Ascites | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Constipation | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Crohn's disease | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Diverticular perforation | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Enteritis | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Gastric ulcer | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Gastric ulcer haemorrhage | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Gastritis | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Gastrointestinal ulcer haemorrhage | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Incarcerated inguinal hernia | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Intestinal haemorrhage | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Intestinal obstruction | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Lower gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Obstructive pancreatitis | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Pancreatitis | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Small intestinal obstruction | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Umbilical hernia | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Upper gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Volvulus | Gastrointestinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Asthenia | General disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Chest pain | General disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0012 affected329 at risk
- EG0020 affected323 at risk
|
| Complication associated with device | General disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Death | General disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0013 affected329 at risk
- EG0021 affected323 at risk
|
| Systemic inflammatory response syndrome | General disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Cholecystitis | Hepatobiliary disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0003 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Cholelithiasis | Hepatobiliary disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Hepatic cirrhosis | Hepatobiliary disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Hepatic failure | Hepatobiliary disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Bacterial sepsis | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Bronchitis | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Cellulitis | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0012 affected329 at risk
- EG0021 affected323 at risk
|
| Clostridium difficile colitis | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Cystitis | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Diverticulitis | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0002 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Endometritis | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Endophthalmitis | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0014 affected329 at risk
- EG0021 affected323 at risk
|
| Enterococcal sepsis | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Erysipelas | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Gastroenteritis | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Gastroenteritis viral | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Herpes zoster | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Infectious pleural effusion | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Infective exacerbation of chronic obstructive airways disease | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0022 affected323 at risk
|
| Kidney infection | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Localised infection | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Lung infection | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Ophthalmic herpes zoster | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Periorbital cellulitis | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Pharyngitis streptococcal | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Pneumonia | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0007 affected318 at risk
- EG0013 affected329 at risk
- EG0025 affected323 at risk
|
| Pneumonia mycoplasmal | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Pyelonephritis | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Sepsis | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0003 affected318 at risk
- EG0013 affected329 at risk
- EG0021 affected323 at risk
|
| Upper respiratory tract infection | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0012 affected329 at risk
- EG0020 affected323 at risk
|
| Urinary tract infection | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0023 affected323 at risk
|
| Urosepsis | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Vaginal infection | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Accidental overdose | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Acetabulum fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Ankle fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0002 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Comminuted fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Fall | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0005 affected318 at risk
- EG0014 affected329 at risk
- EG0025 affected323 at risk
|
| Femoral neck fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Femur fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Foot fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Forearm fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Fracture displacement | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Head injury | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Hip fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0002 affected318 at risk
- EG0011 affected329 at risk
- EG0022 affected323 at risk
|
| Humerus fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Incarcerated incisional hernia | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Incomplete spinal fusion | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Laceration | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Lumbar vertebral fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0012 affected329 at risk
- EG0020 affected323 at risk
|
| Patella fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Pelvic fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Post procedural complication | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Pubis fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0003 affected318 at risk
- EG0012 affected329 at risk
- EG0020 affected323 at risk
|
| Radius fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Rib fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Spinal compression fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Sternal fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Subarachnoid haemorrhage | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Subdural haemorrhage | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Tendon rupture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Traumatic intracranial haemorrhage | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Upper limb fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Wrist fracture | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Electrocardiogram QT prolonged | Investigations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Haemoglobin decreased | Investigations | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| International normalised ratio abnormal | Investigations | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Intraocular pressure increased | Investigations | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG00110 affected329 at risk
- EG0028 affected323 at risk
|
| Dehydration | Metabolism and nutrition disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0012 affected329 at risk
- EG0022 affected323 at risk
|
| Failure to thrive | Metabolism and nutrition disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Fluid overload | Metabolism and nutrition disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Gout | Metabolism and nutrition disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Hypovolaemia | Metabolism and nutrition disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0012 affected329 at risk
- EG0022 affected323 at risk
|
| Costochondritis | Musculoskeletal and connective tissue disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Joint swelling | Musculoskeletal and connective tissue disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Lumbar spinal stenosis | Musculoskeletal and connective tissue disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0002 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Musculoskeletal chest pain | Musculoskeletal and connective tissue disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0004 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Rotator cuff syndrome | Musculoskeletal and connective tissue disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Spinal column stenosis | Musculoskeletal and connective tissue disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Spondylolisthesis | Musculoskeletal and connective tissue disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| B-cell lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Bone cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Breast cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Cervix carcinoma stage IV | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Colon cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Colon neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Gastric cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Hepatic cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Invasive ductal breast carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Laryngeal cancer stage I | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Lip squamous cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Lung adenocarcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Lung cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Lung neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Malignant neoplasm of unknown primary site | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Metastases to central nervous system | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Neoplasm malignant | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Oesophageal cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Pancreatic carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Prostate cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0022 affected323 at risk
|
| Renal cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Salivary gland neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Small intestine carcinoma metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Squamous cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Squamous cell carcinoma of the vulva | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Transitional cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Vulval cancer stage 0 | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Waldenstrom's macroglobulinaemia | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Ataxia | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Balance disorder | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Carotid artery disease | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Carotid artery stenosis | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Cerebral haemorrhage | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Cerebral infarction | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Cerebral ischaemia | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Cerebrovascular accident | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0002 affected318 at risk
- EG0012 affected329 at risk
- EG0021 affected323 at risk
|
| Coma | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Dementia | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Dizziness | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Encephalopathy | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Haemorrhagic stroke | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Hepatic encephalopathy | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| IIIrd nerve paralysis | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Ischaemic stroke | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Lumbar radiculopathy | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Memory impairment | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Metabolic encephalopathy | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Presyncope | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Seizure | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Syncope | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0002 affected318 at risk
- EG0016 affected329 at risk
- EG0021 affected323 at risk
|
| Transient ischaemic attack | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Tremor | Nervous system disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Bipolar disorder | Psychiatric disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Mental disorder | Psychiatric disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Acute kidney injury | Renal and urinary disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0022 affected323 at risk
|
| Bladder cyst | Renal and urinary disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Lower urinary tract symptoms | Renal and urinary disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Nephrolithiasis | Renal and urinary disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Pollakiuria | Renal and urinary disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Renal colic | Renal and urinary disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Benign prostatic hyperplasia | Reproductive system and breast disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Endometrial hyperplasia | Reproductive system and breast disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Prostatomegaly | Reproductive system and breast disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0012 affected329 at risk
- EG0021 affected323 at risk
|
| Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0017 affected329 at risk
- EG0021 affected323 at risk
|
| Chronic respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0022 affected323 at risk
|
| Haemoptysis | Respiratory, thoracic and mediastinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Hypoxia | Respiratory, thoracic and mediastinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0012 affected329 at risk
- EG0020 affected323 at risk
|
| Interstitial lung disease | Respiratory, thoracic and mediastinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Pleural effusion | Respiratory, thoracic and mediastinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Pneumonia aspiration | Respiratory, thoracic and mediastinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Pneumothorax | Respiratory, thoracic and mediastinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Pulmonary hypertension | Respiratory, thoracic and mediastinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Sinus polyp | Respiratory, thoracic and mediastinal disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Skin necrosis | Skin and subcutaneous tissue disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Fracture treatment | Surgical and medical procedures | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Aortic aneurysm | Vascular disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0012 affected329 at risk
- EG0020 affected323 at risk
|
| Aortic stenosis | Vascular disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Circulatory collapse | Vascular disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Deep vein thrombosis | Vascular disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Hypotension | Vascular disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Orthostatic hypotension | Vascular disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Peripheral arterial occlusive disease | Vascular disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Peripheral artery stenosis | Vascular disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Vasculitis | Vascular disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Cataract | Eye disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Posterior capsule opacification | Eye disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Visual acuity reduced transiently | Eye disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0012 affected329 at risk
- EG0021 affected323 at risk
|
| Hypertension | Vascular disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0022 affected323 at risk
|
| Stent-graft endoleak | General disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Cholecystitis acute | Hepatobiliary disorders | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Device related infection | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0010 affected329 at risk
- EG0021 affected323 at risk
|
| Lower respiratory tract infection | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0021 affected323 at risk
|
| Respiratory tract infection | Infections and infestations | MedDRA, version 20.1 | Systematic Assessment | | - EG0001 affected318 at risk
- EG0010 affected329 at risk
- EG0020 affected323 at risk
|
| Brain herniation | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|
| Corneal abrasion | Injury, poisoning and procedural complications | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0022 affected323 at risk
|
| Device malfunction | Product Issues | MedDRA, version 20.1 | Systematic Assessment | | - EG0000 affected318 at risk
- EG0011 affected329 at risk
- EG0020 affected323 at risk
|